Use of Darbepoetin Alfa for the Treatment of Chemotherapy-induced Anaemia in European Clinical Practice - Data From the CHOICE Study

被引：0
|
作者：
Van Belle, S. [1 ]
Galid, A. [2 ]
Karanikiotis, C. [3 ]
Wheeler, T. [4 ]
Pujol, B. [5 ]
Labourey, J. L. [6 ]
机构：
[1] Ghent Univ Hosp, B-9000 Ghent, Belgium
[2] Hanusch KH, Gynecol & Obstet, Vienna, Austria
[3] Euromed Kyanous Stavros Hosp, Theassaloniki, Greece
[4] Amgen Ltd, Int Dev, Uxbridge, Middx, England
[5] Amgen Europe, Int Dev, Zug, Switzerland
[6] Ctr Hosp Antoine Gayraud, Carcassonne, France
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)71217-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [41] A prospective observation study of treatment of chemotherapy-induced anaemia with darbepoetin alfa every 3 weeks:: the OASIS (Observational Aranesp® Survey to Investigate the q3w Schedule) study
    Verhulst, D.
    Pat, K.
    Anrys, B.
    Van Aelst, F.
    Van Eygen, K.
    Galdermans, D.
    Verhoeven, D.
    Polus, M.
    Derde, M. P.
    Vansteenkiste, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 158 - 158
  • [42] European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment
    Repetto, Lazzaro
    Moeremans, Karen
    Annemans, Lieven
    CANCER TREATMENT REVIEWS, 2006, 32 : S5 - S9
  • [43] Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: The 20030125 study group trial
    Glaspy, John
    Vadhan-Raj, Saroj
    Patel, Ravi
    Bosserman, Linda
    Hu, Eddie
    Lloyd, Richard E.
    Boccia, Ralph V.
    Tomita, Dianne
    Rossi, Greg
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2290 - 2297
  • [44] Observational AranespA® Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa
    Pat, K.
    Anrys, B.
    Verhulst, D.
    Van Aelst, F.
    Van Eygen, K.
    Galdermans, D.
    Verhoeven, D.
    Polus, M.
    Segers, K.
    Derde, M. P.
    Wauters, I.
    Vansteenkiste, J.
    SUPPORTIVE CARE IN CANCER, 2009, 17 (02) : 211 - 215
  • [45] Observational Aranesp® Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa
    K. Pat
    B. Anrys
    D. Verhulst
    F. Van Aelst
    K. Van Eygen
    D. Galdermans
    D. Verhoeven
    M. Polus
    K. Segers
    M. P. Derde
    I. Wauters
    J. Vansteenkiste
    Supportive Care in Cancer, 2009, 17 : 211 - 215
  • [46] Evaluating the effectiveness of darbepoetin alfa 300 mcg Q3W for the treatment of chemotherapy-induced anemia
    Boccia, R
    Liu, D
    Silberstein, P
    Tschekmedyian, NS
    Holladay, C
    Tomita, D
    Rossi, G
    Otterson, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 761S - 761S
  • [47] Efficacy of darbepoetin alfa in colorectal cancer patients: Data from the CHOICE study.
    Van Belle, S.
    Urbanski, K.
    Orfeuvre, H.
    Foucher, P.
    Wheeler, T.
    Pujol, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [48] Biosimilar epoetin alfa (HX575) for the treatment of chemotherapy-induced anaemia: Development, approval and 10 years' clinical experience
    Aapro, M. S.
    Krendyukov, A.
    Hoebel, N.
    Seidl, A.
    Gascon, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Erythropoietic agents in routine clinical practice: a retrospective observational survey of epoetin alfa, epoetin beta and darbepoetin alfa use in anaemia patients with cancer
    Pujade-Lauraine, Eric
    Richard, Alain J.
    Sapede, Claudine
    ANNALS OF ONCOLOGY, 2004, 15 : 220 - 220
  • [50] Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia
    Taylor, K
    Ganly, P
    Charu, V
    DiBenedetto, J
    Kracht, K
    Rossi, G
    Hernandez, E
    BLOOD, 2005, 106 (11) : 992A - 993A
12345